Bio Solution
바이오솔루션 · 086820
Health Care Pharmaceuticals · KOSDAQ
Market cap US$133M (₩183.5B)
Overview
Bio Solution develops and supplies cell-therapy products, treatments grown from a patient's own or a donor's cells, used to repair skin damaged by burns and to restore cartilage in joints.
Its products are supplied to hospitals and clinics in South Korea, and it also provides human tissue models used by researchers to test the safety and effectiveness of substances without using animals. Listed on KOSDAQ, Korea's tech and small-cap board, the company runs two distinct business lines: approved, commercialized cell therapies and a contract testing service built around its internationally recognized tissue models.
Summary is AI-generated and may contain errors · figures from DART filings
Financials
Source: DART · FY ending Dec · latest FY2025Revenue
- FY2023US$9M
- FY2024US$9.3M
- FY2025US$11M
Operating profit
- FY2023−US$3.6M
- FY2024−US$3.7M
- FY2025−US$3.1M
Net income
- FY2023−US$905.1K
- FY2024−US$8.6M
- FY2025US$198.1K
Key ratios (FY2025)
Why it matters
Its burn-treatment products are listed under South Korea's national health insurance and industrial-accident insurance schemes, which govern reimbursement and patient access in the Korean market.
Price charts coming soon
Interactive price history isn't here yet. Would you use it?